menu
    • menu
    [{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rifamycin","moa":"DdRP","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Termination","leadProduct":"Rifamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"RedHill Biopharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ RedHill Biopharma","highestDevelopmentStatusID":"14","companyTruncated":"RedHill Biopharma \/ RedHill Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Rifamycin

    Menu

    Rifamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RedHill Biopharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifamycin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : RedHill Biopharma

                            Deal Size : $36.3 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            RedHill Biopharma Terminates License Agreement for Aemcolo®

                            Details : Through termination of the License Agreement, Redhill will regain the rights of Aemcolo (Rifamycin), which is indicated for travelers’ diarrhea caused by noninvasive strains of E.coli in adults.

                            Brand Name : Aemcolo

                            Molecule Type : Small molecule

                            Upfront Cash : $12.0 million

                            July 09, 2024

                            Lead Product(s) : Rifamycin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : RedHill Biopharma

                            Deal Size : $36.3 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cosmo Pharmaceuticals

                            Ireland arrow
                            Fi Europe 2024
                            Not Confirmed

                            Cosmo Pharmaceuticals

                            Ireland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifamycin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : RedHill Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-...

                            Details : The trial investigated the efficacy and safety of two doses of Rifamycin SV-MMX 600mg against placebo after a 2-week course of treatment followed by a 3 months follow-up.

                            Brand Name : Aemcolo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 11, 2021

                            Lead Product(s) : Rifamycin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : RedHill Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth